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Botulinum neurotoxins (BoNTs) cause botulism by cleaving proteins necessary for nerve transmis-
sion. There are seven serotypes of BoNT, A–G, characterized by their response to antisera. Many ser-
otypes are further distinguished into differing subtypes based on amino acid sequence, some of
which result in functional differences. Our laboratory previously reported that all tested subtypes
within each serotype have the same site of enzymatic activity. Recently, three new subtypes of
BoNT/F; /F3, /F4, and /F5, were reported. Here, we report that BoNT/F5 cleaves substrate synaptobre-
vin-2 in a different location than the other BoNT/F subtypes, between 54L and 55E. This is the ﬁrst
report of cleavage of synaptobrevin-2 in this location.
Structured summary of protein interactions:
BoNT/F5 cleaves Synaptobrevin-2 by protease assay (View interaction: 1, 2)
BoNT/F1 cleaves Synaptobrevin-2 by protease assay (View interaction: 1, 2)
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
Open access under CC BY-NC-ND license.1. Introduction each serotype, and this has led to the designation of subtypes,Botulism is a disease which can be fatal if untreated and is
caused by exposure to any one of the highly toxic proteins known
as botulinum neurotoxins (BoNTs). BoNT are composed of a heavy
chain, which binds to receptors on the neuron, and a light chain
that is a protease. In vivo, the BoNT light chain cleaves proteins
necessary for nerve signal transmission. This enzymatic cleavage
leads to ﬂaccid paralysis. Botulinum neurotoxins are currently
classiﬁed into seven serotypes, labeled A–G. BoNT/A, /C, and /E
cleave SNAP-25 (synaptosomal-associated protein) [1–6]whereas
BoNT/B, /D, /F, and /G cleave synaptobrevin-2 (also known as
VAMP-2) [7–11].
Our laboratory previously reported on BoNT’s ability to cleave a
peptide substrate that mimics its natural target, with peptide
cleavage detected by mass spectrometry [12,13]. BoNT/A through
/F are known to exhibit genetic and amino acid variance withine Federation of European Biochem
-25, synaptosomal-associated
ticase-peptone-glucose-yeast
id; TFA, triﬂuoroacetic acid;
A, formic acidsome with identiﬁed antigenic differences [14–16]. However, it
was uncertain if the amino acid variance would also result in dif-
ferential enzymatic activity. Therefore, previous work in our labo-
ratory focused on determining the cleavage location of all available
subtypes of BoNT/A, /B, /E, and /F, the serotypes known to cause
botulism in humans. Previously, 15 such subtypes were available
in sufﬁcient quantities for testing, and all BoNT subtypes within
the same serotype cleaved their respective substrate in the same
location [17]. At the time that this work was reported, only four
subtypes of BoNT/F were known.
In 2010, three new subtypes of BoNT/F; /F3, /F4, and /F5, were
reported based on phylogenetic analysis of botulinum neurotoxin
type F genes [18]. All three subtypes were deﬁned as BoNT/F based
on their ability to cause signs of botulism in mice which could be
prevented by preincubation of toxin with F antitoxins, although
it was reported that the BoNT/F5 toxin required 20 times more
type F antiserum to neutralize an equivalent amount of BoNT/F1
toxin [19]. Additionally, it was noted that BoNT/F5 was highly dif-
ferent in its gene and amino acid sequences compared to the other
BoNT/F subtypes [18]. For instance, Table 1 shows that the whole
toxin (holotoxin) of BoNT/F1 and BoNT/F2 have similar (83.5%
identical) amino acid sequences. However, BoNT/F1 and /F5ical Societies. Open access under CC BY-NC-ND license.
Table 1
Percent amino acid identity between BoNT/F [18].
Holotoxin
F1 F2 F3 F4 F5 F6 F7
F1 – 83.5 83.9 92.3 69.9 87.7 73.7
F2 81.8 – 97.1 83.5 74.2 90.2 68.9
F3 82.9 97.9 – 83.8 74.0 90.1 69.2
F4 96.4 82.7 83.8 – 69.5 87.1 72.2
F5 47.3 46.3 46.3 47.6 – 74.0 63.9
F6 94.3 81.5 82.9 93.6 48.3 – 69.9
F7 63.3 59.5 60.8 64.2 46.9 63.3 –
F1 F2 F3 F4 F5 F6 F7
Enzymatic domain (light chain).
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ilarity (47.3% identity) observed in the light chain (the enzymatic
domain) between BoNT/F5 and BoNT/F1 is even more pronounced.
Until the identiﬁcation of BoNT/F5, this level of variation in the
light chain amino acid sequences within a serotype had not been
reported. Indeed, an amino acid identity of only 47% is much less
than the light chain identity between differing serotypes which
have different sites of enzymatic activity, such as 56% between
BoNT/E and /F and 61% between BoNT/B and /G, based on amino
acid comparison.
The second-most divergent BoNT/F subtype, F7, was reported to
have different peptide substrate recognition requirements [20].
BoNT/F7, produced by Clostridium baratii, is 73.7% identical to
BoNT/F1 at the holotoxin level and 63.3% identical at the enzymatic
domain level. BoNT/F7was reported to cleave both synaptobrevin-2
and peptides based on synaptobrevin-2 in the same location as the
other BoNT/F subtypes, between 58Q and 59K. However, BoNT/F7
did not cleave a peptide substrate cleaved by other available
BoNT/F subtypes based on the sequence of synaptobrevin-2, and
would only cleave TSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKL-
SELDDRADAL, a lengthened peptide substrate [20]. A similar phe-
nomenon was reported with two neurotoxins which also cleave
synpatobrevin-2, BoNT/B and tetanus toxin [21]. This was due to
differential binding of BoNT/F7 with synaptobrevin-2 as compared
to other BoNT/F. Because the amino acid sequence of the BoNT/F5
light chain is even more divergent than BoNT/F7, it was theorized
that BoNT/F5 may have a different molecular reaction with its sub-
strate. In this work, we describe the discovery of a novel enzymatic
cleavage site on synaptobrevin-2 by BoNT/F5.
2. Materials and methods
2.1. Materials
Synaptobrevin-2, SNAP-25, and synatxin recombinant proteins
were purchased from GenWay Biotech, Inc. (San Diego, CA). Mono-
clonal antibody 6F5 was obtained from Dr. James Marks at the
University of California at San Francisco. Dynabeads (M-280/Strep-
tavidin)were purchased from Invitrogen (Carlsbad, CA.) at 1.3 g/cm3
in phosphate buffered saline (PBS), pH 7.4, containing 0.1% Tween-
20 and 0.02% sodium azide. All chemicals were from Sigma-Aldrich
(St. Louis,MO) exceptwhere indicated. Peptide substrates LQQTQAQ
VDEVVDIMRVNVDKVLERDQKLSELDDRADAL and TSNRRLQQTQAQ
VDEVVDIMRVNVDKVLERDQKLSELDDRADAL were synthesized by
Biopeptide (San Diego, CA). Commercially puriﬁed BoNT/F1 (strain
Langeland) was purchased fromMetabiologics (Madison, WI).
2.2. Gene construction of BoNT/F1 and F5 LC-GST
An existing BoNT/F1 LC ORF was PCR ampliﬁed using primers to
add 5’ BamHI and 3’ EcoRI sites. The PCR reaction product was run
on a 1% TAE gel and the ampliﬁed band at approximately 1400 bpwas excised, puriﬁed, ligated into the homologous restriction en-
zymes sites of pGEX6P-1, and transformed into the DH5-a strain
of E. coli. A single recombinant colony was used to inoculate 5 ml
of LB-50 mg/L ampicillin and grown overnight at 37 C. Plasmid
DNA was recovered, completely sequenced to insure accuracy,
mobilized into E. coli strain BL21 DE3, and spread onto LB plates
with 50 mg/L ampicillin. A single recombinant colony was used
to inoculate a LB-50 mg/L ampicillin, grown overnight at 37 C.
The overnight culture was used to inoculate a fresh ﬂask of 1L of
LB-50 mg/L ampicillin and grown to an OD of 0.7, cooled to
18 C, IPTG was added to a ﬁnal concentration of 1 mM, and the
induction was allowed to proceed at 18 C overnight. The same
procedure was followed for BoNT/F5, with the exception that the
BoNT/F5 light chain ORF (representing nucleotides 1-438 from
GU213211.1) was synthesized de novo using a generalized E. coli
K12 codon bias and ligated into the BamHI/EcoRI sites of bacterial
expression vector pGEX6P-1.
2.3. Puriﬁcation of fusion proteins
Both proteins bound to glutathione sepharose resin and were
eluted in the presence of 10 mM reduced glutathione; however,
the protein was not puriﬁed at this stage and required further
chromatography steps. Both proteins were further separated with
cation exchange chromatography after a pH change from 8.0 to
5.7. After cation exchange chromatography the puriﬁed BoNT/
F5 LC-GST was approximately 100 lg/ml, while the BoNT/F1 LC-
GST was approximately 40 lg /ml.
2.4. Production and characterization of BoNT/F5 culture supernatant
CDC54075, originally isolated in March 1978 from soil in a corn-
ﬁeld in Mendoza, Argentina at latitude 34 98’ and longitude 67
59’, was inoculated into 10 mls of Trypticase-Peptone-Glucose-
Yeast Extract (TPGY) broth (Remel, Inc. Lexana, KS) at 35 C for
5 days in an anaerobe chamber system (Coy Laboratory Products,
Inc. Grass Lake, MI) utilizing 10% Hydrogen, 5% CO2, and 85% Nitro-
gen. The culture was tested by PCR for the presence of neurotoxin
genes as previously reported [18]. The culture was centrifuged at
4000g for 10 min and ﬁltered using a 0.45 lm syringe ﬁlter
(Whatman #6876-2504) to remove viable cells. The presence of
botulinum toxin in the culture supernatant was conﬁrmed by ELI-
SA and mouse bioassay [22].
2.5. Reaction of BoNT fusion protein with a peptide or protein target
The BoNT fusion proteins were serially diluted in water to
achieve three different concentrations of each protein. For F1, con-
centrations of 40 lg/ml (52.7 pmol/ml), 4 lg/ml (5.27 pmol/ml),
and 2 lg/ml (2.64 pmol/ml) were used; whereas concentrations
of 100 lg/ml (1.32 nmol/ml), 10 lg/uL (132 pmol/ml), and 5 lg/
ml (66 pmol/ml) were used for F5. 2 ll of each concentration of
fusion protein was added to 16 ll of reaction buffer consisting of
0.05 M Hepes (pH 7.3), 25 mM dithiothreitol, and 20 lM ZnCl2.
Finally, 2 ll of recombinant synaptobrevin-2 or peptide sub-
strate (LQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL or
TSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL) was
added to achieve a ﬁnal concentration of 250 ng/ll (18 pmol/ll)
for synaptobrevin-2 and 50 pmol/ll for the peptide reactions. All
samples then were incubated at 37 C for 4 hrs with no agitation.
2.6. Reaction of BoNT/F5 holotoxin with a peptide or protein target
Monoclonal antibody 6F5, a clonal relative of mAb E17.1 [23]
engineered towardhigherafﬁnity forBoNT/Fsubtypes,was immobi-
lized to streptavidinDynabeads after being rinsed three timeswith
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antibody was used per 100 ll of beads. A standard orbital shaker
was used to bind antibody onto the beads for 1.5 h. An aliquot of
20 ll of antibody-coated beads was added to a solution of 400 ll
of HBS-EP buffer and 100 ll of culture supernatant containing
BoNT/F5. After mixing for 1 h with constant agitation at room tem-
perature, the beadswerewashed twice in 1 ml each ofHBS-EPbuffer
and then once in 100 ll of water. Negative controls consisted of
blank culture supernatant mediumwith no toxin, with the remain-
der of the extractionprotocol as above. Positive controls consisted of
blankculture supernatantmediumspikedwith20mLD50ofBoNT/F1
complex. The level of BoNT/F5 toxin in the culture used was not
known.
The beads were reconstituted in 18 ll of reaction buffer consist-
ing of 0.05 MHepes (pH7.3), 25 mMdithiothreitol, and 20 lMZnCl2
and 2 ll of recombinant synaptobrevin-2 or peptide substrate (LQQ
TQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL or TSNRRLQQT
QAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL). The ﬁnal con-
centration of substrate was 250 ng/ll (18 pmol/ll) for synaptobre-
vin-2 and 50 pmol/ll for the peptide reactions. All samples then
were incubated at 37 C for 4 h with no agitation.
2.7. Peptide mass spectrometric detection
A 2-ll aliquot of each reaction supernatant was mixed with
18 ll of matrix solution consisting of alpha-cyano-4-hydroxy cin-
namic acid (CHCA) at 5 mg/ml in 50% acetonitrile, 0.1% triﬂuoro-
acetic acid (TFA), and 1 mM ammonium citrate. A 0.5-ll aliquot
of this mixture was pipeted onto each spot of a 192-spot matrix-
assisted laser desorption/ionization (MALDI) plate (Applied Biosys-
tems, Framingham, MA). Mass spectra of each spot were obtained
by scanning from 1100 to 4800 m/z in MS-positive ion reﬂector
mode on an Applied Biosystems 4800 Proteomics Analyzer (Fra-
mingham, MA). The instrument uses an Nd-YAG laser at 355 nm,
and each spectrum is an average of 2400 laser shots.
2.8. Protein mass spectrometric detection
All reactions were ﬁrst separated by using a nano-ACQUITY
UPLCTM System (Waters, Milford, MA). Mobile phases were 0.04%
TFA with 0.06% formic acid (FA) in water (mobile phase A) and
0.04% TFA and 0.06% FA in acetonitrile (mobile phase B). Synaptob-
revin-2 and cleavage products were trapped at 500 ng on a Pep-
swift PS-DVB monolithic trapping column, 200 lm x 5 mm
(Dionex, Sunnyvale, CA), and washed for 4 min at a ﬂow rate of
7.5 ll/min with 99% mobile phase A. Intact synaptobrevin-2 and
cleavage products were eluted and separated by using a 70 min
RP gradient at 750 nl/min (1–50% mobile phase B over 35 min)
on a Pepswift PS-DVB monolithic 100 lm  5 cm nanoscale LC col-
umn (Dionex). The column temperature was set to 60 C.
A NanoMate TriVersa (Ithaca, NY) was used for infusion and on-
line LC coupling analysis of the samples at a capillary spray voltage
of 1.82 kV. Themass spectral data were acquired on a Synapt HDMS
QTOF (Waters); the instrument was calibrated for a mass range of
550–4550m/zwith Cesium Iodide through direct infusion. The sam-
pling and extraction cone voltage were optimized at 40 V and 4 V,
respectively, for maximum intact synaptobrevin-2 sensitivity by
comparing on-column injections. Source temperature was set to
150 C. A quadrupole RF transmission proﬁle was deﬁned to trans-
mitmasses from800 to 3500 Da. Trap and transfer collision energies
were set to 6 V and 2 V, respectively, for maximum transmission of
themost abundant synaptobrevin-2 charge states. Thedatawere ac-
quired inTOFV-modeat amass range of 800-3000m/z anda2 scan/s
acquisition time. All datawere processed by using theWatersMass-
LynxMaxEnt 1 software to obtain the deconvolutedmass at a range
of 700–15000 Da with a mass resolution of 0.5 Da. All spectra wereprocessedwith a uniformGaussian damagemodelwith an iterate to
convergence option selected.3. Results
3.1. GST-BoNT/F1 cleaves synaptobrevin-2 as BoNT/F1 holotoxin
The sequence of recombinant synaptobrevin-2 is MRGSHHHHH
HGMASMTGGQQMGRDLYDDDDKDRWGSHMSATAATAPPAAPAGE
GGPPAPPPNLTSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSELD-
DRADALQAGASQFETSAAKLKRKYW, and BoNT/F1, /F2, /F6, and /F7
holotoxins havebeen reported to cleave it in theunderlined location,
between 58Q and 59K [20]. The GST-BoNT/F1 light chain fusion pro-
tein was reacted with recombinant synaptobrevin-2, and Fig. 1
shows that this resulted in two peaks in the mass spectrometer
which correspond to cleavage of recombinant synaptobrevin-2 by
the F1 fusion protein. The peak at mass 13824.0 in Fig. 1A acquired
by electrospray ionization mass spectrometry corresponds to intact
recombinant synaptobrevin-2, whereas the peak at mass 10344.0
corresponds to the N-terminal cleavage product. The peak at m/z
3496.8 in Fig. 1B acquired by MALDI-TOF/MS corresponds to the C-
terminal cleavage product, and the peak at 1749.4 corresponds to
the doubly-charged C-terminal cleavage product. Both cleavage
products demonstrate that the GST-BoNT/F1 light chain fusion
protein cleaves recombinant synaptobrevin-2 between 58Q and
59K, exactly where the BoNT/F1 holotoxin cleaves recombinant syn-
aptobrevin-2.
3.2. GST-BoNT/F1 cleaves peptides which mimic synaptobrevin-2 as
BoNT/F1
Additionally, this fusion protein was tested with two additional
peptide substrates, LQQTQAQVDEVVDIMRVNVDKVLERDQKLSELD-
DRADAL and TSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSEL D-
DRADAL, whose sequences are based upon the sequence of
synaptobrevin-2, and those results are in Figs. 1C and 1D. The peak
atm/z1345.7 in Figs. 1C and1D corresponds to the C-terminal cleav-
age product of the substrates. Note that the C-terminal cleavage
product is the same in both cases, as the two peptides are identical
at the C-terminus. The peak atm/z 3168.6 in Fig. 1C corresponds to
the N-terminal cleavage product of the ﬁrst peptide substrate, and
the peak at m/z 3782.9 in Fig. 1D corresponds to the N-terminal
cleavage product of the second peptide substrate. In both cases,
the GST-BoNT/F1 light chain fusion protein cleaved the peptide sub-
strates in the above-underlined location, corresponding to a location
between 58Q and 59K of synaptobrevin-2. These data demonstrate
that the GST-BoNT/F1 light chain fusion protein has the same activ-
ity upon its substrates as BoNT/F1 holotoxin.
3.3. GST-BoNT/F5 cleaves synaptobrevin-2 and peptides in a different
location
Next, GST-BoNT/F5 light chain fusion protein was reacted with
recombinant synaptobrevin-2. Similar to the reaction with F1, this
resulted in peaks in the mass spectrum corresponding to N-termi-
nal and C-terminal cleavage products, as seen in Fig. 2. However,
the masses of these peaks did not correspond with cleavage be-
tween 58Q and 59K. The peaks at mass 9815.0 (Fig. 2A) and m/z
4025.2 (Fig. 2B) correspond to cleavage between 54L and 55E of syn-
aptobrevin-2, with the peak at m/z 2013.6 corresponding to the
doubly-charged C-terminal cleavage product. The GST-BoNT/F5
light chain fusion protein was also tested with the two peptide
substrates used with BoNT/F1, and those results are in Figs. 2C
and 2D. The peak at m/z 1872.9 in Figs. 2C and 2D corresponds
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Fig. 1. Mass spectra for the reaction of GST-BoNT/F1 light chain fusion protein with recombinant synaptobrevin-2 (1A, 1B), LQQTQAQVDEVVDIMRVNVDKVLERDQK
LSELDDRADAL (1C), and TSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL (1D). Peaks at mass 10344.0, m/z 3496.8, 1345.7, 3168.6, and 3782.9 indicate cleavage
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Fig. 2. Mass spectra for the reaction of GST-BoNT/F5 light chain fusion protein with recombinant synaptobrevin-2 (2A, 2B), LQQTQAQVDEVVDIMRVNVDKVLERDQKL
SELDDRADAL (2C), and TSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL (2D). Peaks at mass 9815.0, m/z 4025.2, 1872.9, 2640.4, and 3254.6 indicate cleavage of
the substrates by the GST-BoNT/F5 light chain fusion protein. Fig. 2A represents protein (ESI) data and Figs. 2B-D represent peptide (MALDI) data.
112 S.R. Kalb et al. / FEBS Letters 586 (2012) 109–115peak at m/z 2640.4 in Fig. 2C corresponds to the N-terminal cleav-
age product of the ﬁrst peptide substrate, and the peak at m/z3254.6 in Fig. 2D corresponds to the N-terminal cleavage product
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Fig. 3. Mass spectra for the reactions of BoNT/F5 holotoxin with recombinant synaptobrevin-2 (S-1A,S-1B), LQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL(S-1C), and
TSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL (S-1D). Peaks at mass 9815.0, m/z 4025.3, 1873.0, 2640.5, and 3254.8 indicate cleavage of the substrates by
BoNT/F5 holotoxin. Fig. 3A represents protein (ESI) data and Figs. 3B-D represent peptide (MALDI) data.
S.R. Kalb et al. / FEBS Letters 586 (2012) 109–115 113chain fusion protein cleaved the peptide substrates in a location
which corresponds to between 54L and 55E of synaptobrevin-2.
3.4. BoNT/F5 holotoxin cleaves synaptobrevin-2 and peptides as GST-
BoNT/F5
Although the light chain of BoNT/F5 exhibits a different cleav-
age pattern than that of the other BoNT/F, it was unclear that this
pattern would be repeated with the holotoxin or progenitor form
of the toxin produced by BoNT/F5-encoding C. botulinum. There-
fore, holotoxin BoNT/F5 was reacted with recombinant synaptob-
revin-2 and the two peptide substrates listed above, and those
results are in Fig. 3. The peaks at mass 9815.0 (Fig. 3A) and m/z
4025.2 (Fig. 3B) correspond to cleavage between 54L and 55E of syn-
aptobrevin-2, with the peak at m/z 2013.9 corresponding to the
doubly-charged C-terminal cleavage product. BoNT/F5 was also
tested with the two peptide substrates used with GST-BoNT/F5,
and those results are in Figs. 3C and 3D. The peak at m/z 1872.9
in Figs. 3C and 3D corresponds to the C-terminal cleavage product
of each of the peptides. The peak at m/z 2640.4 in Fig. 3C corre-
sponds to the N-terminal cleavage product of the ﬁrst peptide sub-
strate, and the peak at m/z 3254.6 in Fig. 3D corresponds to the N-
terminal cleavage product of the second peptide substrate. TheFig. 4. Amino acid sequences of all BoNT/F subtypes in the region of the active site. The a
variant.results are identical to that of Fig. 2, indicating that BoNT/F5 holo-
toxin cleaves synaptobrevin-2 between 54L and 55E, in the same
location as the GST-BoNT/F5 light chain fusion protein.
4. Discussion
As noted above, BoNT/F5 is the most divergent of the botulinum
neurotoxins. Previously BoNT/F7, the second-most divergent of the
botulinum neurotoxins, was shown to interact with its substrate,
synaptobrevin-2, differently from most of the BoNT/F subtypes
since F7 required a longer peptide substrate for cleavage by the
toxin[20]. However the actual cleavage site was identical to the
other known BoNT/F subtypes In contrast, the previously unknown
F5 subtype cleaves the substrate at a different site than all other
BoNT/Fs tested. Of particular interest are several amino acid substi-
tutions near the active site of BoNT/F5 as seen in Fig. 4. The active
site of the toxin, 228E, is conserved among all BoNT/F, and the re-
gion immediately surrounding the active site is also conserved
among all BoNT/F, except for BoNT/F5. With BoNT/F5, three of
the ﬁve amino acids immediately upstream of the active site differ
from all other BoNT/F. This degree of variance so close to the active
site is an important factor in the ability of this toxin to cleave syn-
aptobrevin-2 in a different location.ctive site (228E) is in red. Residues in blue indicate regions where BoNT/F5 is the only
Table 2
Amino acid contacts between residues 25 and 57 of synaptobrevin-2 and BoNT/F1 [24]. Sequence alignments with all other BoNT/F are also included, with mutations shown in red
and conserved mutations shown in green.
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counts for its ability to cleave synaptobrevin-2 in a differentlocation from all other BoNT/F. These amino acid differences are lo-
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of BoNT/F5 with synaptobrevin-2. Of the amino acids in BoNT/F1
which are reported to be important for interactions with synaptob-
revin-2, there are many which are mutated in BoNT/F5. Table 2
lists the residues of synaptobrevin-2 from 25N to 57D and their re-
ported contact with corresponding residues of BoNT/F1 [24], with
added sequence alignments of all other BoNT/F. Of the 28 amino
acids in BoNT/F5 expected to be contacted by residues 25N to 57D
of synaptobrevin-2, approximately three-quarters are signiﬁcantly
altered from that of BoNT/F1, with 20 of the 28 residues differing
signiﬁcantly. This is in contrast to the other BoNT/F, in which 0
to 14 residues differ. Six of the amino acids from 25N to 57D of syn-
aptobrevin-2—33Q, 39V, 41E, 43V, 54L, and 57D—reduce the cleavabil-
ity of synaptobrevin-2 by more than 66% when mutated,
demonstrating that these residues are critical for binding of syna-
ptobrevin-2 to BoNT/F1 [21]. Four of those six residues contact mu-
tated residues on BoNT/F5, which could explain why residues 25N
to 70L of synaptobrevin-2 bind BoNT/F5 differently, resulting in dif-
ferential cleavage. It should be noted that BoNT/F5 was found to
cleave only synaptobrevin-2 and not additional SNARE proteins
such as SNAP-25 or a truncated version of syntaxin (data not
shown).
Cleavage between 54L and 55E of synaptobrevin-2, has never
been reported for any botulinum neurotoxin. BoNT/B, /D, and /G
are also known to cleave snaptobrevin-2, but these toxins cleave
between 76Q and 77F, 59K and 60L, and 81A and 82A of synaptobre-
vin-2, respectively [7,10,11]. Additionally, up to this point, all sub-
types within a serotype have been reported to share the same
cleavage site. Knowledge of a new cleavage site of BoNT will be
of particular interest to scientists involved in developing medical
countermeasures for botulism. Many scientists are investigating
inhibitors such as peptide substrate blockers and mAb as next gen-
eration botulism therapeutics. Additionally, some botulism diag-
nostic methods are being developed which are based on activity
towards a protein or peptide substrate. This report of a unique sub-
strate cleavage site by BoNT/F5 subtype will alert scientists to po-
tential functional variability within BoNT serotypes. Therefore, it is
important to study the enzymatic activity of newly-emerging bot-
ulinum neurotoxins in order to design effective inhibitors of BoNTs
and assays to detect all BoNTs.
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